Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics

被引：9

作者：

Roland, Lauren T. ^{[1
]}

Regenberg, Alan ^{[2
]}

Luong, Amber U. ^{[3
]}

Wise, Sarah K. ^{[4
]}

Toskala, Elina ^{[5
]}

Lam, Kent K. ^{[6
]}

Levy, Joshua M. ^{[4
]}

Franzese, Christine B. ^{[7
]}

Smith, Kristine ^{[8
]}

Kim, Jean ^{[9
]}

机构：

[1] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA

[2] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA

[3] Univ Texas Hlth Sci Ctr Houston, Dept Otolaryngol Head & Neck Surg, McGovern Med Sch, Houston, TX 77030 USA

[4] Emory Univ, Dept Otolaryngol Head & Neck Surg, Atlanta, GA 30322 USA

[5] Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA

[6] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA

[7] Univ Missouri, Dept Otolaryngol Head & Neck Surg, Columbia, MO USA

[8] Univ Manitoba, Dept Otolaryngol Head & Neck Surg, Winnipeg, MB, Canada

[9] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 4940 Eastern Ave, Baltimore, MD 21224 USA

来源：

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY | 2021年 / 11卷 / 11期

关键词：

chronic rhinosinusitis; medical therapy of chronic rhinosinusitis; rhinosinusitis; ENDOTYPES; OUTCOMES; ASTHMA;

D O I：

10.1002/alr.22864

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Biologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short-term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost-effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various treatment options, counseling regarding side effect profiles, and healthcare economics also need to be addressed.

引用

页码：1524 / 1528

页数：5

共 23 条

[21] Cost-effectiveness of omalizumab in adults with severe asthma: Results from the asthma policy model [J].

Wu, Ann C. ;

Paltiel, A. David ;

Kuntz, Karen M. ;

Weiss, Scott T. ;

Fuhlbrigge, Anne L. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (05) :1146-1152

[22] Association Between Oral Corticosteroid Bursts and Severe Adverse Events A Nationwide Population-Based Cohort Study [J].

Yao, Tsung-Chieh ;

Huang, Ya-Wen ;

Chang, Sheng-Mao ;

Tsai, Shun-Yu ;

Wu, Ann Chen ;

Tsai, Hui-Ju .

ANNALS OF INTERNAL MEDICINE, 2020, 173 (05) :325-+

[23]

Zimmermann M., 2018, DRUGS DERMATOL

← 1 2 3 →